which was designed to evaluate MRK’s anti-PD-1 therapy Keytruda and the Japanese pharma giant’s tyrosine kinase inhibitor Lenvima for a certain type of cancer in the gastrointestinal tract.
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback